Effects of phenytoin on man's immunity. Evaluation of changes in serum immunoglobulins, complement, and antinuclear antibody.
To determine the effects of phenytoin on serum immunoglobulins, complement, and antinuclear antibody conversion, a prospective, five-year longitudinal study was undertaken in 118 patients. Three major diagnostic groups were evaluated: 27 patients with idiopathic epilepsy, 50 with secondary epilepsy, and 41 with neuropathic syndromes without epilepsy. In addition, 83 normal volunteers were studied in a similar manner. Evaluations were performed prior to administration of phenytoin and at six-month intervals thereafter. Prior to treatment, patients with idiopathic epilepsy had a higher than expected incidence (13.5 percent, p less than 0.01) of low serum IgA (less than 61 mg/dl). Patients with secondary epilepsy and neuropathic disorders without epilepsy had a greater than expected incidence (9.2 percent, p less than 0.01; and 12 percent, p less than 0.01, respectively) of high serum IgA (greater than 417 mg/dl). Phenytoin treatment was associated with further decreases in serum IgA in patients with idiopathic epilepsy (p = 0.063) and secondary epilepsy (p = 0.008). Total serum IgE concentrations also decreased significantly in all patient categories during treatment with phenytoin. Minor decreases in serum IgG and IgM were noted, but serum IgD and complement remained unaffected. Antinuclear antibodies were observed with essentially the same frequency (10 percent) before and after phenytoin therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis*; D002493:Central Nervous System Diseases / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003176:Complement C3 / Q000032:analysis*; D003181:Complement C4 / Q000032:analysis*; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis*; D007073:Immunoglobulin E / Q000032:analysis*; D007075:Immunoglobulin M / Q000032:analysis*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000494:pharmacology*; D011446:Prospective Studies
D000974:Antibodies, Antinuclear; D003176:Complement C3; D003181:Complement C4; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D007073:Immunoglobulin E; D010672:Phenytoin